Molecular Templates Inc (OQ:MTEM)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 9301 Amberglen Blvd Ste 100
AUSTIN TX 78729-1153
Tel: N/A
IR: See website
Key People
Harold E. Selick
Chairman of the Board
Jason Kim
President, Chief Operating Officer
Eric E. Poma
Chief Executive Officer, Chief Scientific Officer, Director
Adam D. Cutler
Chief Financial Officer, Treasurer, Secretary
Roger Waltzman
Chief Medical Officer
Business Overview
Molecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs). The Company is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. The Company's lead drug candidate MT-3724 is an is an immunotoxin that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias.
Financial Overview
For the six months ended 30 June 2020, Molecular Templates Inc revenues decreased 11% to $11.1M. Net loss increased from $15.3M to $53.2M. Revenues reflect Research and development revenue - from decrease of 71% to $3.4M. Higher net loss reflects Rese increase from $17.7M to $48.2M (expense), General and admi increase of 24% to $9.6M (expense), Stock based Expenses in R&D increase from $1M to $2.8M (expense).
Employees: 219 as of Jun 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $538.73M as of Jun 30, 2020
Annual revenue (TTM): $20.87M as of Jun 30, 2020
EBITDA (TTM): -$82.22M as of Jun 30, 2020
Net annual income (TTM): -$107.35M as of Jun 30, 2020
Free cash flow (TTM): -$56.80M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 49,919,267 as of Aug 4, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.